AOD-9604 Peptide: What It Is, How It Works, and What the Evidence Shows

AOD-9604 is a lab-made 16-amino-acid fragment of human growth hormone (hGH) — specifically residues 176-191 — that researchers designed to copy hGH's fat-burning effect without its blood-sugar or growth side effects [1]. It is not FDA-approved for weight loss or any other medical indication [4], and its largest human trial (534 adults, 24 weeks) did not beat placebo [2]. In the U.S., it is only legally accessible as a compounded preparation through a licensed 503A pharmacy with a clinician's prescription [4].

What is AOD-9604?

AOD-9604 (short for "Anti-Obesity Drug 9604," also written as Tyr-hGH 176-191) is a short synthetic peptide. It copies the last 16 amino acids of human growth hormone and adds a tyrosine residue at the start for stability [1]. Researchers at Monash University and the Australian company Metabolic Pharmaceuticals isolated this fragment in the 1990s because earlier animal work suggested the fat-burning activity of hGH lived in its C-terminal tail, separate from its growth-promoting activity [1][7]. It is important to state upfront: AOD-9604 is not FDA-approved as a drug for any condition [4].

Origin as a growth hormone fragment

Full human growth hormone is a 191-amino-acid protein. It does many things at once: it triggers growth, raises IGF-1, breaks down stored fat, and can raise blood sugar [1]. The hope behind AOD-9604 was to keep only the fat-breakdown signal — the part of the molecule that tells fat cells to release stored energy — and leave the rest behind [1][7].

How it differs from full-length hGH

In animal studies, AOD-9604 broke down fat without raising IGF-1 levels and without changing insulin sensitivity in a way that would push blood sugar up [1][7]. That made it look attractive on paper. In practice, the largest human trial did not show meaningful weight loss versus placebo [2], and long-term human safety has not been established.

How does AOD-9604 work in the body?

AOD-9604's proposed mechanism is lipolysis — the breakdown of stored triglycerides in fat cells into free fatty acids that the body can burn for energy [1]. In rodent and isolated-cell studies, the peptide appeared to act through the beta-3 adrenergic receptor pathway, which is heavily involved in fat metabolism in brown and white fat tissue [1][7]. Human evidence for a clinically meaningful effect is weak [2].

Lipolysis and the beta-3 adrenergic pathway

Activating beta-3 adrenergic receptors tells fat cells to release stored fat and, in some tissues, to burn it as heat [7]. AOD-9604 nudged this pathway in mice, raising fat oxidation and reducing body weight in obese animal models [1][7]. Side effects reported in human trials — most commonly mild gastrointestinal symptoms, headache, and injection-site reactions — should be considered alongside the modest evidence of benefit [2][8].

Why it doesn't raise IGF-1 or impair insulin sensitivity

Unlike full hGH, AOD-9604 does not appear to bind the main growth hormone receptor in a way that drives IGF-1 production [1]. In trial participants, blood sugar and IGF-1 levels stayed near baseline [2]. That short-term metabolic neutrality is a real safety advantage compared with hGH — but only matters if the drug actually works for its intended use, which the pivotal trial did not confirm [2].

Does AOD-9604 actually work for weight loss?

The honest answer: the strongest human trial said no. AOD-9604's largest Phase IIb study, run by Metabolic Pharmaceuticals, enrolled 534 obese adults and tested several doses of AOD-9604 against placebo over 24 weeks. The peptide did not produce statistically significant weight loss versus placebo, and Metabolic Pharmaceuticals discontinued development as a weight-loss drug shortly after [2]. Side effects in the program were generally mild and similar to placebo, but long-term safety has not been studied [2][8].

What the clinical trials showed

Earlier, smaller human studies (Phase I and Phase IIa) had hinted at modest fat loss and good tolerability [2]. The pivotal Phase IIb trial was designed to confirm those signals at scale — and it did not [2]. In short: the rodent data looked great, the small early human data looked promising, and the larger human trial did not back it up.

Why development was discontinued in 2007

When a drug fails its main efficacy endpoint at the Phase IIb stage, sponsors usually stop development for that indication. That is what happened here [2]. Metabolic Pharmaceuticals later licensed AOD-9604 for use as a food additive — it received GRAS (Generally Recognized as Safe) status in 2014 — but the weight-loss drug program ended [3]. GRAS status is a food-ingredient designation; it is not FDA drug approval [3][4].

Animal versus human results

AOD-9604 is a good example of a peptide where animal results overpromised. Obese mice lost weight in early studies [1]; obese humans, in the controlled Phase IIb setting, did not lose more weight than people on placebo [2]. This is common in obesity research and is one reason regulators rely on adequately powered human trials before approving weight-loss drugs.

How much weight can you lose on AOD-9604?

Based on the published human data, AOD-9604 has not been shown to produce meaningful weight loss beyond what placebo produces [2]. Online clinics and compounding pharmacies sometimes quote anecdotal numbers, but these reports are not from controlled trials. Individual results vary, and no provider can ethically promise a specific number of pounds lost. Reported side effects — mild GI symptoms, headache, injection-site reactions — should be weighed against this modest and unproven benefit [2][8].

Realistic expectations

A realistic read of the evidence: if AOD-9604 helps at all in humans, the effect is small and not reliably bigger than diet and exercise alone [2]. Compare that to GLP-1 receptor agonists investigated as treatments for obesity, where Phase III trials report average weight loss of about 15% of body weight with semaglutide 2.4 mg over 68 weeks [5] and about 20% with tirzepatide 15 mg over 72 weeks [6]. Those medications carry their own side effects, including nausea, vomiting, constipation, and rare reports of pancreatitis and gallbladder issues, as described on their FDA labels [5][6].

Role of diet and exercise

Every credible weight-loss intervention works better with consistent nutrition and movement [5][6]. That is doubly true for AOD-9604, where the drug effect itself is uncertain. Most of any observed change will be coming from the lifestyle side.

What dose of AOD-9604 was used in research?

Doses studied in published research range from about 1 mg to 30 mg per day, given orally over 24 weeks in the Phase IIb trial [2]. Earlier Phase I studies tested both oral and injectable forms [2]. This article describes doses used in published research only — it is not a dosing protocol, and specific doses should never be self-selected. Any use should be under the direct supervision of a licensed clinician.

Doses studied in clinical trials

The Phase IIb arms used a range of doses precisely to find a dose-response signal. None reached statistical significance over placebo at 24 weeks [2]. In other words, more drug did not equal more weight loss in the controlled human data.

Why higher doses didn't help

There are a few possible reasons: short peptide half-life, limited oral bioavailability, receptor desensitization, or simply that the mechanism that worked in mice does not translate to humans at any tolerable dose [2][7]. The trial sponsors did not find a higher dose that rescued the result [2].

How long can you stay on AOD-9604?

The longest published controlled human exposure to AOD-9604 is the 24-week Phase IIb trial [2]. Long-term safety and efficacy beyond six months have not been studied in adequately powered trials. Some compounding-pharmacy programs use shorter cycles, but there is no strong human evidence guiding optimal duration. Decisions about length of use should be made with a clinician who can monitor for side effects (including GI symptoms and injection-site reactions) and reassess whether continued use is justified [2][8].

What are the side effects and safety concerns?

Across the AOD-9604 development program, more than 900 participants received the peptide. Reported side effects were generally mild and similar to placebo, with no consistent signal for serious cardiovascular, glycemic, or growth-related adverse events [2]. The most commonly reported issues were mild gastrointestinal symptoms, headache, and, with injection, occasional injection-site reactions [2][8]. Because the largest human trial did not show meaningful benefit [2], any side effect — even a mild one — needs to be weighed against an unproven benefit.

Findings from 900+ trial participants

The Phase IIb program's safety profile was reassuring on the basics: no meaningful change in IGF-1, no clinically meaningful blood-sugar elevations, and no consistent change in vital signs versus placebo [2]. That short-term safety profile is one reason compounding pharmacies still prepare it on prescription, even though efficacy is unconvincing [2][4].

Unknown long-term effects and contraindications

What we do not have: long-term safety data in healthy adults using AOD-9604 for cosmetic fat loss over years. There is no large cardiovascular outcomes trial, no pregnancy data, and no data in adolescents [2]. People with a history of cancer, active growth hormone disorders, pregnancy, or breastfeeding should not use AOD-9604 outside a clinical trial. Anyone considering it should be evaluated by a clinician first.

How does AOD-9604 compare to GLP-1s like semaglutide and tirzepatide?

This is the most useful comparison most readers want, so here it is plainly. Semaglutide (brand names Wegovy and Ozempic; also available as compounded semaglutide through licensed 503A pharmacies) and tirzepatide (brand names Zepbound and Mounjaro; also available as compounded tirzepatide) are GLP-1 receptor agonists — a drug class with large, FDA-reviewed Phase III trials behind them [5][6]. Both are FDA-approved for chronic weight management in adults who meet label criteria; both carry class-specific risks documented on their FDA labels (including risk of thyroid C-cell tumors in rodent studies, pancreatitis, gallbladder disease, and GI side effects) [5][6]. AOD-9604 has none of those efficacy data — and no FDA approval [4].

Bottom line: for someone whose primary goal is meaningful weight loss, the GLP-1 class has far stronger human evidence [5][6]. AOD-9604 is more accurately described as an investigational fat-metabolism peptide whose pivotal trial did not succeed [2]. If you want to read more, see our guides on compounded semaglutide and compounded tirzepatide.

Is AOD-9604 legal or FDA-approved?

AOD-9604 is not FDA-approved as a drug for weight loss or any other medical indication [4]. It received GRAS status in 2014 as a food ingredient, which is a separate and much narrower designation [3]. Selling it for human use as a drug without a prescription is not legal in the U.S.; many online "research chemical" vendors operate in a gray zone and are not legitimate sources for human use [4].

Research-use status

Vials labeled "research use only" are not quality-controlled for human injection. Purity, sterility, and dose accuracy are not guaranteed [4]. This is a well-documented safety risk.

Role of 503A compounding pharmacies

503A compounding pharmacies are state-licensed pharmacies that can prepare patient-specific medications based on a prescription from a licensed clinician [4]. In the U.S., this is the legitimate pathway for compounded AOD-9604. The FDA is actively reviewing peptide ingredients used in compounding, and AOD-9604's status in that pathway may change [9] — readers should check FDA.gov for current status before proceeding.

What peptides stack well with AOD-9604?

In clinical and compounding-pharmacy practice, AOD-9604 is sometimes combined with other peptides aimed at related goals. None of these peptides are FDA-approved for fat loss in healthy adults, and combination-specific human safety data is limited [4][9]. These are not Chia-recommended protocols.

• CJC-1295 + Ipamorelin: this pair is investigated for stimulating the body's own growth-hormone axis. Safety caveat: overlapping effects on appetite, water retention, and IGF-1 elevation mean lab monitoring is appropriate, and these peptides are not FDA-approved for this use [9].
• Tesamorelin: a growth-hormone-releasing hormone analog FDA-approved specifically for HIV-associated lipodystrophy that has been studied for visceral fat in other populations [10]. Safety caveat: raises IGF-1; not appropriate for people with active cancer or untreated retinopathy; off-label use should be clinician-supervised.
• BPC-157: sometimes added for tissue and gut support during a fat-loss program. Safety caveat: BPC-157 is not FDA-approved and is currently under FDA compounding review [9]; human safety data is limited.

Any combination should be designed and monitored by a licensed clinician familiar with peptide therapy. Combined dosing is outside the scope of this article.

How to access AOD-9604 safely through a licensed provider

If, after reading the evidence above, you and your clinician decide AOD-9604 is appropriate to try, the safest path in the U.S. is a prescription dispensed by a licensed 503A compounding pharmacy [4]. That means: a real clinical evaluation, a real prescription, a real pharmacy that tests for sterility and potency, and follow-up to track response and side effects.

Several legitimate telehealth platforms offer this pathway. Below is a short, honest comparison of the kinds of providers patients typically consider. Placement is alphabetical, not ranked.

There are other reputable providers; the important thing is that the provider is licensed in your state, uses a real clinical evaluation, and works with accredited compounding pharmacies. Eligibility for any compounded peptide depends on state law, your medical history, and clinical judgment.

Many patients who initially ask about AOD-9604 end up discussing GLP-1 options instead because the evidence base is much stronger [5][6] — but that decision belongs to you and your clinician. Individual results vary, and no honest provider can guarantee an outcome.

Frequently asked questions

Keep reading

GLP-1 & Weight Loss

Microdosing GLP-1s: What It Means, Who It's For, and What the Evidence Says

Weight Loss

Peptides for Weight Loss: How They Work and What to Know

GLP-1 Weight Loss

How to Get Weight Loss Injections: A Step-by-Step Guide